МОЛЕКУЛЯРНО-КОМПЛЕКСНОЕ СОЕДИНЕНИЕ, ФОТОПОЛИМЕРИЗУЮЩИЙСЯ СОСТАВ И СПОСОБ ФОТОПОЛИМЕРИЗАЦИИ

FIELD: polymerization processes. SUBSTANCE: molecular-complex compound consists of (i) mono- or bis-acylphosphine oxide of formula I: (I), in which R 1 and R 2 , independently from each other, denote C1-C12-alkyl, phenyl optionally 1-4-fold substituted by C1-C8-alkyl and/or C1- C8-alkoxyl, or COR 3 group; R 3 denotes phenyl optionally 1-4-fold substituted by C1-C8-alkyl and/or C1-C8-alkoxyl; and (ii) alpha- hydroxyketone compound of formula II: R 11 (II), in which R 12 and R 11 , independently from each other, denote C1-C6- alkyl or R 12 and R 13 , together with carbon atom to which they are linked, form cyclohexyl ring; R 14 represents hydroxy; and Эс гс ПЧ сэ (19) РОССИЙСКОЕ АГЕНТСТВО ПО ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ ВИ” 2181 726. (51) МПК? 13) С2 С 07Е 9/53, С 08 Е 2/46 12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ РОССИЙСКОЙ ФЕДЕРАЦИИ (21), (22) Заявка: 97114452/04, 25.08.1997 (24) Дата начала действия патента: 25.08.1997 (30) Приоритет: 28.08.1996 СН 2115/96 (43) Дата публикации заявки: 10.06.1999 (46) Дата публикации: 27.04.2002 (56) Ссылки: Ц$ 4737593 А, 12.04.1988. ЦЗ 4792632 А, 20.12.1988. СВ 2259104 А, 24.03.1993. КУ 2057159 СЛ, 10.04.1996. (98) Адрес для переписки: 107078, Москва, Красноворотский пр-д, д.3, корп.1, к.311, Патентно-правовая фирма "Искона |", пат.пов.Гавриловой Е А. (71) Заявитель: ЦИБА СПЕШИАЛТИ КЕМИКАЛЗ ХОЛДИНГ ИНК. (СН) (72) Изобретатель: ЛЕППАРД Давид Георг (СН), ДЖЕЙМС Томас Ллойд (СН), ХЕК Нильс (ОЕ), КЕЛЛЕР Манфред (0Е), САЛАТЕ Рональд (0Е) (73) Патентообладатель: ЦИБА СПЕШИАЛТИ КЕМИКАЛЗ ХОЛДИНГ ИНК. (СН) (74) Патентный поверенный: Гаврилова Елена Аркадьевна (54) МОЛЕКУЛЯРНО-КОМПЛЕКСНОЕ СОЕДИНЕНИЕ, ФОТОПОЛИМЕРИЗУЮЩИЙСЯ СОСТАВ И СПОСОБ ФОТОПОЛИМЕРИЗАЦИИ (57) Изобретение относится К молекулярно-комплексному соединению, состоящему из моно- или бисацилфосфинокисного соединения формулы (1!) где К и К обозначают независимо друг от друга С41-С12-алкил, незамещенный или замещенный один-четыре раза С1-Сз-алкилом и/или С1-Сз-алкоксилом фенил или группу СОК ...

Способ получения 5-[4-(4-ацетил-3-гидрокси-2-пропилбензилокси)бензил]-тетразола

Изобретение касается замещенных гетероциклических веществ, в частности получения 5-[4-(4-ацетил-3-гидрокси-2-пропилбензилокси)-бензил]тетразола, используемого для лечения аллергических заболеваний, например астмы. Цель - создание нового более активного вещества указанного класса. Синтез ведут реакцией азида тетраметилгуанидиния с 4-[4-ацетил-3-гидрокси-2-пропилбензилокси]фенилацетонитрилом в среде диметилформамида в атмосфере аргона при 120-123°С. Выход 55,8%, т.пл. 155-157°С, брутто-ф-ла C20H22N4O3. Новое вещество малотоксично и имеет более высокий срок службы (6 ч, против 0,6 мин в известном случае). 1 табл.

BENZYLALKOHOLDERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND SIE ENTHALTENDE PHARMAZEUTISCHE MITTEL

ANTIDIABETISCHE MITTEL

BENZO-1,3-DIOXANES

... 1455174 Benzo-1,3-dioxanes BASF AG 26 Feb 1974 [27 Feb 1973] 8617/74 Heading C2C Novel benzo-1,3-dioxanes having the general formula wherein R1 is halogen, trifluoromethyl, nitro, cyano or a radical of the formula -COR4 wherein R4 is hydrogen, (C 1 -C 4 ) alkyl, hydroxy, alkoxy, or an unsubstituted or mono- or disubstituted amino, and R2 and R3 are (C 1 -C 4 )- alkyl or together form a methylene chain of from 3 to 6 carbon atoms, are prepared by reacting an o-hydroxymethylphenol substituted by R1 in the para position to the phenolic hydroxy group with a ketone of the formula in an aprotic solvent or solvent mixture and in the presence of a water-binding agent. The novel compounds possess fungicidal properties.

PROCESS FOR CARRYING OUT REACTIONS USING SUBSTITUTED HYDROXY-ALKYLPHENONES AS PHOTOSENSITISERS

Novel benzylalcohol derivative and process for preparing the same

A benzylalcohol derivative of the formula: (I) wherein R is hydroxy, benzyloxy, alkoxy of one to 4 carbon atoms or halogen, and Ring A is monomethoxyphenyl, dimethoxyphenyl, trimethoxyphenyl or 3,4-methylenedioxyphenyl is prepared by reducing a compound of the formula: wherein R' is benzyloxy, alkoxy of one to 4 carbon atoms or halogen, and Ring A is the same as defined above, and when R' is benzyloxy, if required, further subjecting the product to catalytic hydrogenation. The compounds (I) and pharmaceutically acceptable acid addition salts thereof are used as anti-diabetic agents.

INITIATORS FOR THE PHOTO POLYMERIZATION

COSMETIC ONE, THE WELDING FORMATION RESTRAINING MEANS

ANTIDIABETI MEANS

Ketone compounds and compositions for cholesterol management and related uses

ETHANOLAMINES

Aromatic derivatives and iron complexes thereof for the use as normalising agents of the iron level

ANTI-PERSPIRANTS

LEUKOTRIENE ANTAGONISTS

This invention provides novel benzene derivatives which are leukotriene antagonists, formulations of those derivatives, intermediates for preparing the derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotxienes. More specifically the invention as disclosed provides compounds of the Formula I and pharmaceutically acceptable salts thereof, wherein: R1 is hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, phenyl-substituted-(C1-13 alkyl), phenyl, or phenyl substituted with halo, C1-C4 alkyl, or C1-C4 alkoxy; R2 is C1-C10 alkyl, C2-C6 alkenyl, benzyl, or 2-phenylethyl; R3 is hydrogen, bromo, or chloro; Z is -O , -NR-, or , or when taken together, m is 0-4; A is a bond, -o-, -NR, -?-'', or -CHOH-; n is 0-4, Q is a bond, -O-, , or -NR " -; and R4 is -CN, hydroxy, -SC(=NH)NH2, -NR14-R15, or ; where each of R, R', and R'' is independently hydrogen or C1-C3 alkyl; each of R5 and ...

COMPOSITIONS COSMETIQUES ANTIPERSPIRANTES, NOUVEAUX COMPOSES ET PROCEDE DE PREPARATION DE CES COMPOSES

AROMATIC DERIVATIVES AND IRON COMPLEXES THEREOF FOR THE USE AS NORMALISING AGENTS OF THE IRON LEVEL

The present invention is directed to aromatic derivatives of formula (I), wherein: R1 is (a), wherein R3 and R4 are selected from between H and OH, provided that R3 and R4 are not simultaneously H, and R2 is H; or R1 and R2 taken together, are (b), wherein R5 is selected from between CH3 and (CH2)5OH, to the iron complexes thereof, and to their use for the preparation of pharmaceutical compositions for the normalisation of iron level.

ANTIFUNGAL AGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND INTERMEDIATES

A compound represented by the general formula: (see formula 1) wherein R1 and R2 denote a halogen atom or hydrogen atom; R3 means a hydrogen atom or lower alkyl group; ~ , r and m stand for 0 or 1; A is N or CH; W denotes an aromatic ring or a condensed ring thereof; X means another aromatic ring, an alkanediyl group, an alkenediyl group, or an alkynediyl group; Y stand for -S-, etc.; Z denotes a hydrogen atom, etc., or a salt thereof, and intermediates thereof or a salt thereof as well as processes for the preparation thereof, and pharmacetical composition suitable for use as an antifungal agent.

FULLERENE DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE

Fullerene derivatives, methods of preparing them and their use Fullerene derivatives of the formula I where the symbols and indices have the following meanings: F: is a fullerene radical of the formula C(20+2m) where m = 20, 25, 28, 29; E1, E2: are identical or different and are each COOH, COOR, CONRR1, CHO, COR, CN, P(O)(OR) 2 and SO2R, where R, R1 are each a straight-chain or branched, aliphatic radical (C1 to C20) which may be unsubætituted or monosubstituted or polysubstituted by identical or different substituents, in which radical up to every third CH2 unit can be replaced by O or NR4, where R4 is (C1-C20)-alkyl or benzyl, or a benzyl radical or phenyl radical which can be unsubstituted or substituted by from 1 to 5 substituents R, OH, OR, COOR, OCOR, SO3H, SO2Cl, F, Cl, Br, NO2 and CN or together are or are different from one another and are each COR, R or H, or are different from one another and are each COR/R or F/Cl/Br, where R is as defined above, or are different ...

ANTIDIABETIC AGENTS

The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.

THERAPEUTIC AGENT FOR DIABETES

A therapeutic agent for diabetes comprising a compound represented by general formula (I) ¢wherein X represents (a), (b) or (c)! ¢wherein R4 and R5, which may be the same or different, represent a hydrogen atom, or an optionally substituted alkyl group having 1 to 5 carbon atoms and R6 represents a hydrogen atom or an amino protective group; R1 represents an optionally substituted alkyl group having 1 to 5 carbon atoms or an optionally substituted alkenyl group having 2 to 6 carbon atoms; R2 represents a hydrogen atom or an optionally substituted alkyl group having 1 to 5 carbon atoms; R2' represents a hydrogen atom; and R3 represents an optionally substituted alkyl group having 1 to 5 carbon atoms!, a prodrug compound thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof. The agent has an excellent blood sugar lowering activity in the case of a high blood sugar level, does not influence the blood sugar in the case of a normal blood sugar level, that ...

Verfahren zur Herstellung eines Aryloxynaphthylketons.

Verfahren zur Herstellung eines Aryloxynaphtylketons.

Verfahren zur Herstellung eines Aryloxynaphtylketons.

Verfahren zur Herstellung eines Aryloxynaphtylketons.

Verfahren zur Herstellung eines Aryloxynaphtylketons.

Verfahren zur Herstellung eines Aryloxynaphtylketons.

Verfahren zur Herstellung eines Aryloxynaphtylketons.

Verfahren zur Herstellung eines Aryloxynaphtylketons.

Verfahren zur Herstellung eines Aryloxynaphtylketons.

Verfahren zur Herstellung eines Aryloxynaphtylketons.

Verfahren zur Herstellung eines Aryloxynaphtylketons.

Verfahren zur Herstellung eines Aryloxynaphtylketons.

Verfahren zur Herstellung eines Aryloxynaphtylketons.

Verfahren zur Herstellung eines Aryloxynaphtylketons.

Verfahren zur Herstellung von Tetrahydropyran- und Tetrahydrofuranverbindungen

COMPOSITION COSMETIQUE ANTI-PERSPIRANTE.

Verfahren zur Herstellung von neuen Fluoranthylketonen

BENZYLE ALCOHOL DERIVATIVES AND PROCEDURES FOR THEIR PRODUCTION.

HYDROXYALKYLPHENONE AND YOUR USE AS PHOTOSENSIBILISATOREN.

BENZYLE ALCOHOL DERIVATIVES, YOUR PRODUCTION AND IT ABSTENTION PHARMACEUTICAL PREPARATIONS.

FLUORENE DERIVATIVES.

5-[(3,3,3-ТРИФТОР-2-ГИДРОКСИ-1-АРИЛПРОПИЛ)АМИНО]-1H-ХИНОЛИН-2-ОНЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ПРОТИВОВОСПАЛИТЕЛЬНЫХ СРЕДСТВ

Настоящее изобретение относится к соединениям формулы I способам их получения и их применению в качестве противовоспалительных средств.

is 5th [(3,3,3-TRIFLUORO-2- HYDROXy -1-[ARILPROPIL]) AMINO] - 1H- QUINOLINE -2-[ONY], THE METHOD OF THEIR OBTAINING and THEIR APPLICATION AS THE ANTIPYRETIC MEANS

BENZO-1,3-DIOXANES

METHOD OF PREPARATION Of ALKYL-2 INDANE

ALCOHOLS ARALKYLIQUES

METHOD OF PREPARATION Of ACIDS 2-ARYLALCANOIQUES AND THEIR SALTS AND ESTERS

BENZO-1

AQUEOUS DISPERSION COMPRISING A U.V. ABSORBING COMPOUND

Aqueous dispersion comprising at least one U.V. absorbing compound of the following formula (I) (forumula see on enclosed paper version) wherein R1 to R4 independently of each other are hydrogen; C1-4 alkyl; substituted C2-4-alkyl; -oc1-4alkyl; Oaryl; COC1-2alkyl; COOC1-2alkyl; aryl- or substituted aryl-radicals,a process of treating a textile material with said dispersions as well as textiles treated with such a dispersion.

Leukotriene antagonist intermediates

This invention provides novel benzene derivatives which are leukotriene antagonists, formulations of those derivatives, intermediates for preparing the derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.

Optically active epoxy compounds and processes for their production

An optically active epoxyenone derivative of the following formula (1): wherein R¹ is a methyl group, an ethyl group or a C_3-10 branched, linear or cyclic alkyl group, and R² is a phenyl group, a substituted phenyl group or a tert-butyl group.

Triazole compounds, their production and use

Production of aromatic carbonyl compounds including novel acetophenones

A hydroperoxide of the formulae (A)-1 or (A)-2: wherein R1 and R² are each a hydrogen atom or a methyl group and R3 and R4 are each a hydrogen atom, a (C1-C3)alkyl group, or a carboxyiic acid ester group, is decomposed in an inert gas atmosphere in the presence of an aqueous layer containing an iron salt, a copper salt and an acid to form a corresponding aromatic carbonyl compound of the formulae (B)-1 or (B)-2: ...

Molecular complexes as photoinitiators

СОЕДИНЕНИЯ АЗОЛА, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ПРОТИВОГРИБКОВОЙ АКТИВНОСТЬЮ

FIELD: organic chemistry, fungicides, pharmacy. SUBSTANCE: invention describes new azole compounds of the general formula (I) where values A, R 1 -R 3 , W, X, Y, Z, m are given in the p. 1 of the invention claim and can be used for treatment of patients with dermatomycosis, visceromycosis. Invention describes also a method of their synthesis, intermediate compounds and the pharmaceutical composition showing an antifungal activity. EFFECT: improved method of synthesis, enhanced effectiveness of compositions. 31 cl, 6 tbl, 165 ex ДУбСУГС ПЧ Го (19) РОССИЙСКОЕ АГЕНТСТВО ПО ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (51) МПК ВИ” 2142 947 Сл С 070 233/60, 249/08, 417/06, 417/14, 409/06, 413/06, 409/14, 403/10, 513/04, А 61 К ЗЛ/АЛ, А 01 М 43/653 12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ РОССИЙСКОЙ ФЕДЕРАЦИИ (21), (22) Заявка: 95101828/04, 06.02.1995 (24) Дата начала действия патента: 06.02.1995 (30) Приоритет: 07.02.1994 /Р 33268/94 05.07.1994 УР 174894194 10.08.1994 УР 208203/94 09.12.1994 УР 306467/04 (46) Дата публикации: 20.12.1999 (56) Ссылки: ЗИ 1251802 АЗ, 1986. ЕР 0044605 АЛ, 1982. ОЕ 2920314 05$, 1984. ЕР 0047594 А2, 1982. (98) Адрес для переписки: 129010, Москва, ул.Б.Спасская 25, стр.3, ООО "Городисский и Партнеры" (71) Заявитель: Эйсай Ко., Лтд. (Р) (72) Изобретатель: Тосихико Наито (.Р), Кацура Хата (}Р), Юмико Каку ()Р), Акихико Цуруока (Р), Итару Цукада (Р), Манабу Янагисава (/Р), Тосио Тойосава (.Р), Казумаса Нара (.Р) (73) Патентообладатель: Эйсай Ко., Лтд. (Р) (54) СОЕДИНЕНИЯ АЗОЛА, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ПРОТИВОГРИБКОВОЙ АКТИВНОСТЬЮ (57) Реферат: Описываются новые соединения азола общей формулы 1, где значения А, В! - ВЗ, \/, Х, У, 2, т указаны в п.1 формулы, которые проявляют противогрибковую активность и могут быть использованы при лечении дерматомикоза, висцеромикоза. Описывается также способ их получения, промежуточные соединения, а также фармацевтическая композиция, обладающая ...

СПОСОБ ПОЛУЧЕНИЯ МОНОГИДРАТОВ КАЛИЕВЫХ СОЛЕЙ 1-(ГЕТ)АРИЛ-4,4,4-ТРИФТОРБУТАН-1,3-ДИОНОВ, ОБЛАДАЮЩИХ ПРОТИВОМИКРОБНОЙ И АНАЛЬГЕТИЧЕСКОЙ АКТИВНОСТЯМИ

Группа изобретений относится к области органической химии и включает моногидраты калиевых солей 1-(гет)арил-4,4,4-трифторбутан-1,3-дионов (1-8) общей формулы: , где R=C6H5 (1), 4-Me-C6H4 (2), 4-MeO-C6H4 (3), 4-F-C6H4 (4), 4-Cl-C6H4 (5), 4-Br-C6H4 (6), 4-NO2-C6H4 (7), 2-тиенил (8), и способ их получения. Способ осуществляют путем прикапывания спиртового раствора 1-замещенного-4,4,4-трифторбутан-1,3-диона к охлажденному до 0°С водному раствору гидроксида калия при перемешивании. Затем реакционную смесь выдерживают в течение 15 мин при охлаждении, затем еще 15 мин при комнатной температуре, выпавший осадок отфильтровывают и отмывают хлороформом. Технический результат: моногидраты калиевых солей 1-(гет)арил-4,4,4-трифторбутан-1,3-дионов (1-8), обладающие противомикробной и анальгетической активностями. 2 н.п. ф-лы, 2 табл., 10 пр.

NEUE BENZO-1,3-DIOXANE

Improvements relating to organic compounds

ANTI PERSPIRANTS

... 1366435 Cyclic aluminium derivatives of substituted 1,3-diols L'OREAL 10 Oct 1972 [16 Dec 1971] 46695/72 Heading C2C [Also in Divisions A5 and C4] Novel compounds having the general Formula I in which R represents Cl; -OSO 2 R1 where R1 is C 1-4 alkyl, phenyl, p-chlorophenyl, p-hydroxyphenyl, p-tolyl or 2-ono-10-bornanyl or a -O-R11 radical in which R11 is CH 3 , C 2 H 5 , isoC 3 H 7 or tertC 4 H 9 and Z is either (a) a radical of Formula II in which R 1 is (i) a COR 3 radical wherein R 3 is CH 3 or C 2 H 5 when R 2 is CH 3 , or R 3 is phenyl when R 2 is CH 3 acetyl or CO 2 -C 1-4 alkyl; (ii) a radical CO 2 C 1-4 alkyl when R 2 is CH 3 , CN or CO 2 C 1-4 alkyl; or (iii) an NO 2 radical when R 2 is Br or C 1-3 alkyl or (b) a radical of Formula III in which R, represents either (i) CH 3 , when R 6 is CO 2 -C 1-4 alkyl and R 5 is -O-C 1-4 alkyl; or (ii) a hydrogen atom when R 6 represents a COR 9 radical where R 9 is CH 3 and R 5 is CH 3 or phenyl or R 9 ...

ARALKYL CARBOXYLIC ACID COMPOUNDS

... 1512541 Quinones and phenols TAKEDA YAKUHIN KOGYO KK 2 May 1975 [2 May 1974] 18538/75 Heading C2C Novel compounds I to IV in which R=C 1-4 alkyl or C 1-4 alkoxy A is CH 2 , CO or CH(OH), n is 1 to 8, X is H or OH, which may be protected and Y is OH, which may be protected, and esters thereof, are prepared as shown in the following reaction scheme: Pharmaceutical compositions having a beneficial action on the lysosomal membranes of cells and also physiological host defence control activity and smooth muscle relaxant activity, for oral or parenteral activity, comprise one of the above novel compounds together with a pharmaceutical carrier.

Manufacture of oxybenzofluorenones

Oxybenzofluorenones are made by condensing an oxynaphthylphenyl ketone of the general formula wherein X stands for a hydrogen atom, with an acid condensing agent. The products dissolve in caustic alkali to a red-violet solution, preferably in presence of an auxiliary such as turkey-red oil, react with diazo compounds to give azo-dyes, and their alkali salts have affinity for cellulose fibres. Thus 1-oxy-3:4-benzofluorenone may be coupled on the fibre with diazotized 4.4<1>-dichlor-2-aminodiphenyl ether to yield a bordeaux tent and with diazotized 4-amino-3-methoxy-azobenzene or 4-amino-3-methoxy-6-methyl-4<1>-chlorazobenzene to give a fast black shade. In examples, 2-oxynaphthalene-3-phenyl ketone or its 4<1>-methyl derivative is melted with aluminium chloride. The oxynaphthylphenylketones used as starting materials are made by condensing a halide of 2.3-oxynaphthoic acid with benzene or a derivative.

KOSMETISCHE, DIE SCHWEISSBILDUNG HEMMENDE MITTEL

INITIATOREN FUER DIE PHOTOPOLYMERISATION

PROCEDURE FOR the PRODUCTION OF 2-ALKYL AND/OR 2-CYCLOALKYLINDENEN

PHOTO INITIATORS FOR THE PHOTO POLYMERIZATION OF INSATIATED SYSTEMS.

PROCEDURE FOR THE PRODUCTION OF NEW BENZO-1,3-DIOXANEN

DERIVATIVES OF AROMATICS AND THEIR IRON OF COMPLEXES FOR USE AS REGULATING AGENTS OF THE IRON MIRROR

Novel intermediates useful for the preparation of antihistaminic piperidine derivatives

Novel intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives

FLUORENE DERIVATIVES

KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES

The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES

The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

AQUEOUS DISPERSION COMPRISING A U.V. ABSORBING COMPOUND

Aqueous dispersion comprising at least one U.V. absorbing compound of the following formula (I) (forumula see on enclosed paper version) wherein R1 to R4 independently of each other are hydrogen; C1-4 alkyl; substituted C2-4- alkyl; -oc1-4alkyl; Oaryl; COC1-2alkyl; COOC1-2alkyl; aryl- or substituted aryl-radicals,a process of treating a textile material with said dispersions as well as textiles treated with such a dispersion.

MOLECULAR COMPLEX COMPOUNDS COMPRISING A MONO-, BIS- OR TRISACYLPHOSPHINE OXIDE WITH AN .ALPHA.-HYDROXY KETONE AS PHOTOINITIATORS

Molecular complex compounds comprising a mono-, bis- or trisacylphosphine oxide compound with an .alpha.-hydroxy ketone compound are suitable as photoinitiators for the photopolymerization of free-radically polymerizable compounds.

PROCESS FOR THE PREPARATION OF BETA-HYDROXY-CARBONYL COMPOUNDS

Antidiabetic and/or hypolipaemic aromatic cpds. - e.g. 4'-(1-hydroxy-2,2-dimethylpropyl)-acetophenone

NEW ORGANIC COMPOUNDS, THEIR PREPARATION AND USE THEREOF AS DRUGS

NEW PHOTOINITIATORS

The invention relates to novel photoinitators of formulae (I), (II), (III), (IV), (V) and (VI) wherein R1 and R2 are each independently of the other C1-C8alkyl; C1-C4alkyl substituted by OH, C1-C4alkoxy, -COO(C1-C8alkyl), (C1-C4alkyl)-COO-, -CN, benzyl, phenyl or by -N(R15)(R16); C3-C6alkerlyl, benzyl, -CH2-C6H4-(C1-C4alkyl) or phenyl; or R1 and R2 together are unbrarched or branched C2-C9alkylene or C3-C6-oxa- or -aza–alkylene; R3, R4, R5 and R6 are each independently of the others hydrogen, C1-C8alkyl, C3-C6alkenyl, benzyl, -CH2-C6H4-(C1-C4alkyl) or phenyl; R3 and R4 together and/or R5 and R6together are unbranched or branched C2-C9alkylene; A is CI, Br, -O-R9, -N(R11)(R12) or -S-R18, A' is -O-, -NH- or -NR11-; A" is CI, Br, -O-R9, -N(R11)(R12) or -S-R18 or hydrogen, X is -O-R10or -N(R13)(R14), n is an integer from 1 to 10, preferably an integer from 1 to 4, especially 1, 2 or 3; R7 is a linker; R8is a bivalent C2-C3alkylele radical.

PHOTOLABILE FRAGRANCE STORAGE SUBSTANCES

Photolabile fragrance storage substances are described, which are capable of photoinduced release of odorant aldehydes and odorant ketones. Additionally described are a process for long-lasting fragrancing of surfaces and a process for producing the fragrance storage substances mentioned.

Ketone compounds and compositions for cholesterol management and related uses

The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Process for producing optically active gamma-hydroxyketones

PROCESS FOR THE PREPARATION OF 1-HYDROXYKETONES

FLUORENE DERIVATIVES

SENSITIZER FOR THE PHOTO POLYMERIZATION

NEW PHOTO INITIATORS

PROCEDURE FOR THE PRODUCTION OF NEW BENZO-1,3-DIOXANEN

AROMATIC INHIBITORS OF ACETYLCHOLINESTERASE

NEW INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF ANTIHISTAMIN 4 - DIPHENYLMETHYL/DIPHENYLMETHOXYPIPERIDIN DERIVATIVE N

MOLECULE COMPLEX CONNECTIONS AS PHOTO INITIATORS

PROCEDURE FOR the PRODUCTION OF 2-ALKYL AND/OR 2 - CYCLOALKYLINDANEN

Ketone compounds and compositions for cholesterol management and related uses

Novel intermediates useful for the preparation of antihistaminic pipe ridine derivatives

AROMATIC ALIPHATIC KETONE SENSITIZERS FOR PHOTOPOLYMER- ISATION

ETHANOLAMINES

PRODUCTION OF OPTICALLY ACTIVE TRIAZOLE COMPOUNDS AND THEIR INTERMEDIATES

A compound of the formula (V): (V) , wherein Ar' is a halogenated phenyl group, R is a hydrocarbon residue having a functional group at the .alpha.-carbon, R3' is an optionally substituted aliphatic or aromatic hydrocarbon residue or an optionally substituted aromatic heterocyclic group, Y and Z are, the same or different, a nitrogen atom or a methine group optionally substituted with a lower alkyl group, and (R) and (S) represent configurations, which is an optically active intermediate for production of optically active triazole compounds (I): (I) , wherein the symbols have the same meanings as defined above, and methods of preparing the compounds (V) and (I).

Sugar plant derived by-products and methods of production thereof

The present document describes a nutraceutical or cosmeceutical composition for the prophylaxis of an ailment comprising a therapeutically effective amount of a sugar plant syrup filtration residue in association with a pharmaceutically acceptable carrier. The present document also describes a nutraceutical or cosmeceutical composition for improving health condition of skin. The present document describes a method of producing a sugar plant syrup-derived product; wherein the improvement is characterized in the step of: collecting a sugar plant syrup residue during the production of sugar or syrup to produce a syrup-derived by-product.

AROMATIC PERFLUOROALKANE MONOMER

An aromatic perfluoroalkane monomer is provided that can be used for the manufacture of a polymer membrane for a PEM-type fuel cell. The perfluoroalkane monomer has a structure corresponding to a formula (I): 110-. (canceled)12. The monomer according to claim 11 , wherein n is in a range from 2 to 20.13. The monomer according to claim 11 , wherein n is in a range from 2 to 8.14. The monomer according to claim 11 , wherein Zand Z claim 11 , which are identical or different claim 11 , are chosen from a group that includes: halogens claim 11 , hydroxyl claim 11 , alkoxyls claim 11 , thiol claim 11 , carboxyl claim 11 , carboxylates claim 11 , amino claim 11 , sulphonamido claim 11 , acyl chloride claim 11 , sulphonyl chloride claim 11 , sulphonyl fluoride claim 11 , isocyanate claim 11 , and combinations thereof.15. The monomer according to claim 14 , wherein the monomer corresponds to a formula (I-2):{'br': None, 'sub': 3', '1', '2', 'n', '2', '4, 'F—Ar—CO—Ar—(CF)—Ar—CO—Ar—F.\u2003\u2003(I-2)'}16. The monomer according to claim 14 , wherein the monomer corresponds to a formula (I-3):{'br': None, 'sub': 3', '1', '2', 'n', '2', '4, 'HO—Ar—CO—Ar—(CF)—Ar—CO—Ar—OH.\u2003\u2003(I-3)'}17. The monomer according to claim 11 , wherein n is equal to 4.18. The monomer according to claim 12 , wherein n is equal to 4.19. The monomer according to claim 13 , wherein n is equal to 4.20. The monomer according to claim 14 , wherein n is equal to 4.21. The monomer according to claim 15 , wherein n is equal to 4.22. The monomer according to claim 16 , wherein n is equal to 4.23. The monomer according to claim 11 , wherein the monomer is a sulphonic monomer carrying a sulphonic (—SOH) group or a sulphonate (—SOM) group claim 11 , in which M represents an alkali metal cation.24. The monomer according to claim 23 , wherein the sulphonic (—SOH) group or the sulphonate (—SOM) group is carried by a phenyl group or a phenylene group claim 23 , or by a substituent thereof. The present invention ...

Novel phytochemicals from extracts of maple syrups and maple trees and uses thereof

The present invention describes phytochemicals present in maple syrup and maple tree extracts by butanol, ethyl acetate and methanol. Novel compounds are isolated from maple syrups, including one compound Quebecol generated in the maple syrup manufacturing process. Also described are digesting extract of maple syrup. The phytochemicals may be used for the treatment or prevention of cancers, metabolic syndromes, diabetes, microorganism infections and/or antioxidants.

Phenolic compound having carbonyl as neighboring group and application thereof

To provide a liquid crystal compound having a large negative value of dielectric anisotropy (Δ∈). A compound is represented by formula (1): wherein, in formula (1), R 1 and R 2 are hydrogen, halogen or alkyl having 1 to 10 carbons, and in the alkyl, at least one of —CH 2 — may be replaced by —O—, at least one of —(CH 2 ) 2 — may be replaced by —CH═CH—, and at least one of hydrogen may be replaced by halogen; ring A 1 and ring A 2 are 1,4-cyclohexylene or 1,4-phenylene; Z 1 is a single bond, —(CH 2 ) 2 —, —CH 2 O—, —OCH 2 —, —CF 2 O—, —OCF 2 —, —COO—, or —OCO—; Y is halogen, —CF 3 , —CF 2 H or —CH 2 F; and m, n and p are 0, 1 or 2, and a sum (m+n) of m and n is 0, 1 or 2.

Process for Preparing Benzofurans

There is provided a process for the preparation of a compound of formula (I), wherein R, R, R, R, X and Y are as described in the description. Such compounds may, for example, be useful intermediates in the synthesis of drugs such as Dronedarone. 132.-. (canceled)352. The compound of claim wherein Z represents phenyl substituted in the para-position by —OH , —OCHor —O-benzyl. This application is a Divisional of U.S. application Ser. No. 12/681,299, filed Jul. 28, 2010; which is a National Stage of International Application No. PCT/GB08/003,341, filed Oct. 2, 2008; which claims the benefit of priority from GB Application No. 0719180.2, filed Oct. 2, 2007, the entire contents of which are incorporated by reference in their entirety.The present invention relates to a process for the manufacture of various benzofurans by reaction of an arylhydroxylamine and a ketone, and the use of such benzofurans in the synthesis of compounds, e.g. drugs, containing such cores, for instance anti-arrhythmia drugs such as Dronedarone (N-{2-(n-butyl)-3-[4-(3-dibutylamino-propoxy)-benzoyl]-benzofuran-5-yl}methane-sulfonamide).Dronedarone is a Class III anti-arrhythmia drug for the prevention of cardiac arrhythmias such as atrial fibrillation (AF). AF is a condition characterised by an irregular heart beat and occurs when the atria (the upper chambers of the heart) contract very rapidly. This causes the lower chambers of the heart, the ventricles, to contract chaotically so that blood is inefficiently pumped to the body which can lead to tissue damage and even death.Dronedarone is prepared via a stepwise procedure which involves the synthesis of a number of intermediates, including 2-butyl-3-(4-methoxybenzoyl)-5-nitrobenzofuran and 2-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran.2-Butyl-3-aroyl-5-nitrobenzofurans are typically synthesised via Friedel-Craft acylation of 3-unsubstituted 2-butyl-5-nitrobenzofurans. Such reactions are described in U.S. Pat. No. 5,223,510 and U.S. Pat. No. 5,854 ...

Compositions and processes of preparing and using the same

The present invention relates to compositions, for example, the DBU/Hexafluoroacetone hydrate salt, and processes of preparing and using the same for the modification of chemical compounds via the release of trifluoroacetate. The DBU/Hexafluoroacetone hydrate salt can perform trifluoromethylation reactions on chemical compounds, such as carbonyl group-containing compounds.

METHOD FOR PURIFICATION OF 4-HYDROXYACETOPHENONE

Methods of purifying crude 4-hydroxyacetophenone using one or more solvents as well as products comprising or consisting of crystallized 4-hydroxyacetophenone and one, two or more solvent(s). The products may be obtained or obtainable from the methods for purifying crude 4-hydroxyacetophenone. 112-. (canceled)13. A method of purifying crude 4-hydroxyacetophenone comprising:(a) providing crude 4-hydroxyacetophenone,(b) mixing the crude 4-hydroxyacetophenone of step (a) with two or more solvents to obtain a mixture,(c) optionally, heating the mixture obtained in step (b) to dissolve the 4-hydroxyacetophenone,(d) optionally, adding an adsorbent to the mixture of step (b) or step (c), if present,(e) optionally, cooling the mixture of step (b), step (c) or step (d), if present, to a temperature above the crystallization temperature of 4-hydroxyacetophenone,(f) if step (d) is present, removing the adsorbent from the mixture of step (d) or step (e), if present,(g) cooling of the mixture of step (b) or step (c), if present, or further cooling of the mixture obtained in step (e), if step (d) is not present, or step (f), if present, to a temperature below the crystallization temperature of 4-hydroxyacetophenone to induce crystallization of 4-hydroxyacetophenone and to obtain crystallized 4-hydroxyacetophenone, 'optionally, carrying out steps (i) to (k) one or more times:', '(h) collecting the crystallized 4-hydroxyacetophenone, and'}(i) dissolving the crystallized 4-hydroxyacetophenone of step (h) or step (k) in two or more solvents, optionally under heating, to produce a solution,(j) cooling of the solution of step (i) to a temperature below the crystallization temperature of 4-hydroxyacetophenone to induce crystallization of 4-hydroxyacetophenone and to obtain crystallized 4-hydroxyacetophenone,(k) collecting the crystallized 4-hydroxyacetophenone obtained in step (j), 'wherein each of the two or more solvents used in steps (b) and (i), if present, is independently selected ...

ELECTROCHEMICALLY ACTIVE AGENTS FOR PH MODULATION IN BIOLOGICAL BUFFERS

Device and methods for use in a biosensor comprising a multisite array of test sites, the device and methods being useful for modulating the binding interactions between a (biomolecular) probe or detection agent and an analyte of interest by modulating the pH or ionic gradient near the electrodes in such biosensor. An electrochemically active agent that is suitable for use in biological buffers for changing the pH of the biological buffers. Method for changing the pH of biological buffers using the electrochemically active agents. The methods of modulating the binding interactions provided in a biosensor, analytic methods for more accurately controlling and measuring the pH or ionic gradient near the electrodes in such biosensor, and analytic methods for more accurately measuring an analyte of interest in a biological sample. 1. An electrochemically active composition comprising a quinone derivative , wherein:a reactivity between a nucleophile and the quinone derivative is reduced compared to a reactivity between the nucleophile and an unsubstituted quinone from which the quinone derivative is derived, andthe composition is configured such that the pH of the composition is electrochemically modulated via the quinone derivative.3. The composition of claim 2 , wherein all of the R groups of the quinone derivative are different from each other.4. The composition of claim 2 , wherein two or more of the R groups of the quinone derivative are the same.5. The composition of claim 1 , wherein the composition is an aqueous solution.6. The composition of claim 1 , further comprising an additive selected from the group consisting of: an aqueous buffer claim 1 , an organic solvent claim 1 , an electrolyte claim 1 , a buffer salt claim 1 , a bioreagent claim 1 , a biomolecule claim 1 , a surfactant claim 1 , a preservative claim 1 , a cryoprotectant claim 1 , and combinations thereof.7. The composition of claim 1 , wherein the one or more nucleophiles are selected from the group ...

UBIQUITIN-SPECIFIC PEPTIDASE 24 INHIBITOR, MEDICINAL COMPOSITION INCLUDING THE SAME AND METHOD OF DELAYING OR REVERSING MULTIDRUG RESISTANCE IN CANCERS USING THE SAME

The present invention relates to a ubiquitin-specific peptidase 24 inhibitor, a medicinal composition including the same and a method of delaying or reversing multidrug resistance in cancers using the same. The USP24 inhibitor, which includes a shUSP24 RNA and/or a carbonyl substituted phenyl compound, can serve as a chemosensitizing agent for inhibiting the drug pump out, cancer sternness and genomic instability of cancer cells, thereby being applied to a medicinal composition and a method for delaying or reversing multidrug resistance in cancers. 6. The USP24 inhibitor of claim 1 , wherein the siRNA is a double-stranded USP24 RNA claim 1 , a short-hairpin USP24 (shUSP24) RNA claim 1 , an isolated ribonucleic acid sequence or a viral siRNA construct claim 1 , and the viral siRNA construct is a lentiviral siRNA construct.12. The medicinal composition of claim 7 , wherein the salt of the carbonyl substituted phenyl compound is selected from the group consisting of oxalate claim 7 , phosphate claim 7 , sulfate and chloride.13. The medicinal composition of claim 7 , wherein the siRNA is a double-stranded USP24 RNA claim 7 , and the siRNA is an isolated ribonucleic acid sequence or a viral siRNA construct.14. The medicinal composition of claim 7 , wherein the viral siRNA construct is a lentiviral siRNA construct claim 7 , and a value of m.o.i. of the lentiviral siRNA is 2.5 to 10.15. The medicinal composition of claim 7 , wherein a dosage of the carbonyl substituted phenyl compound is 12.5 mg/kg to 25 mg/kg of body weight.16. The medicinal composition of claim 7 , wherein the cancer cell is a solid tumor cell or a blood cancer cell claim 7 , and the cancer cell is selected from the group consisting of a lung cancer cell claim 7 , a nasopharyngeal carcinoma cell claim 7 , a brain cancer cell claim 7 , a colorectal carcinoma cell claim 7 , a lymphoma cell claim 7 , a leukemia cell and a multiple myeloma cell. This application is a Continuation-in-part of U.S. application ...

ANTIBACTERIAL AGENTS: PHLOROGLUCINOL DERIVATIVES

The invention provides a compound of formula I: 3. A composition comprising a compound of formula I as described in claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable vehicle.4. A method for inhibiting a bacterial RNA polymerase comprising contacting the bacterial RNA polymerase with a compound of formula I as described in claim 1 , or a salt thereof.5. A method for inhibiting the growth of a bacterium comprising contacting the bacterium with a compound of formula I as described in claim 1 , or a salt thereof.6. A method for treating a bacterial infection in a mammal comprising administering to the mammal an effective amount of a compound of formula I as described in claim 1 , or a pharmaceutically acceptable salt thereof.78-. (canceled)9Mycobacterium tuberculosis, Staphylococcus aureusEnterococcus faecalis, Enterococcus faecium, Bacillus anthracis, Escherichia coli, Haemophilus influenzae, Moraxella catarrhalis, Francisella tularensis,Burkholderia mallei.. The method of claim 6 , wherein the bacteria is selected from MSSA and MRSA claim 6 , and10. (canceled)11. The composition of claim 3 , in the form of a disinfectant claim 3 , sterilant claim 3 , antispoilant claim 3 , or antiseptic.12. A composition comprising a compound of formula I as described in claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , and a pharmaceutically acceptable vehicle.13. The composition of claim 12 , in the form of a disinfectant claim 12 , sterilant claim 12 , antispoilant claim 12 , or antiseptic.14. A method for treating a bacterial infection in a mammal comprising administering to the mammal an effective amount of a compound of formula I as described in claim 2 , or a pharmaceutically acceptable salt thereof.15Mycobacterium tuberculosis, Staphylococcus aureusEnterococcus faecalis, Enterococcus faecium, Bacillus anthracis, Escherichia coli, Haemophilus influenzae, Moraxella catarrhalis, Francisella tularensis,Burkholderia ...

TRPV-1 RECEPTOR ANTAGONIST COMPOUND DERIVED FROM 1,3,4-THIADIAZOLE ALKYLAMIDES AND CHALCONES

This technology encompasses compounds derived from 1,3,4-thiadiazole alkylamides and chalcone, which inhibit the activation of the TRPV-1 receptor using capsaicin and temperature. Also disclosed is the use of these compounds in the treatment of diseases with TRPV-1 overexpression, such as chronic pain. 1. Compounds derived from 1 ,3 ,4-thiadiazol alkylamides wherein they inhibit TRPV-1 receptor activation.2. Compounds derived from 1 claim 1 ,3 claim 1 ,4-thiadiazol alkylamides claim 1 , according to claim 1 , wherein they inhibit the capsaicin and temperature activation of the TRPV-1 receptor.3. Compounds derived from 1 claim 1 ,3 claim 1 ,4-thiadiazol alkylamides claim 1 , according to claim 1 , wherein their R structure is a saturated alkyl chain defined by saturated linear chains of 6 to 8 carbons where X is defined as a H atom or an iodine atom.4. Compounds derived from 1 claim 1 ,3 claim 1 ,4-thiadiazol alkylamides claim 1 , according to claim 1 , wherein they are obtained through O-acylation reaction claim 1 , amine condensation claim 1 , oxidative cyclization of thiosemicarbazone claim 1 , N-acylation reaction and alkaline hydrolysis.5. Compounds derived from 1 claim 1 ,3 claim 1 ,4-thiadiazol alkylamides claim 1 , according to claim 1 , wherein they correspond specifically to the following compounds:a) N-[5-(4-hydroxy-5-methoxy-3-iodophenyl)-1,3,4-thiadiazole-2-yl]nonamide,b) N-[5-(4-hydroxy-3-methoxyphenyl)-1,3,4-thiadiazole-2-yl]-nonamide,c) N-[5-(4-hydroxy-5-methoxy-3-iodophenyl)-1,3,4-thiadiazole-2-yl]-octanamide,d) N-[5-(4-hydroxy-3-methoxyphenyl)-1,3,4-thiadiazole-2-yl]-octanamide,e) N-[5-(4-hydroxy-5-methoxy-3-iodophenyl)-1,3,4-thiadiazole-2-yl]-heptanamide,f) N-[5-(4-hydroxy-3-methoxyphenyl)-1,3,4-thiadiazole-2-yl]-heptanamide,g) N-[5-(4-hidroxy-5-methoxy-3-iodophenyl)-1,3,4-thiadiazole-2-yl]-hexanamide, andh) N-[5-(4-hydroxy-3-methoxyphenyl)-1,3,4-thiadiazole-2-yl]-hexanamide.6. Compounds derived from chalcones claim 1 , wherein they inhibit the ...

METHOD FOR PURIFICATION OF 4-HYDROXYACETOPHENONE

Methods of purifying crude 4-hydroxyacetophenone using one or more solvents as well as products comprising or consisting of crystallized 4-hydroxyacetophenone and one, two or more solvent(s). The products may be obtained or obtainable from the methods for purifying crude 4-hydroxyacetophenone. 2. The method according to claim 1 , wherein the one or more solvent(s) used in steps (b) and (i) claim 1 , if present claim 1 , independently comprise one of the following combinations:ethanol/water,ethyl acetate/cyclohexane,dimethyl carbonate/cyclohexane,butyl acetate/cyclohexane, ordiethyl carbonate/cyclohexane.3. The method according to claim 1 , wherein in step(s) (b) and/or (i) claim 1 , if present claim 1 , independently 0.5 to 70 wt. % of 4-hydroxyacetophenone claim 1 , based on the total weight of the mixture obtained in step (b) or step (i) claim 1 , respectively claim 1 , is combined with the one or more solvent(s).4. The method according to claim 1 , wherein in step (c) claim 1 , the mixture obtained in step (b) is heated to reflux.5. The method according to claim 1 , wherein in step (d) claim 1 , 0.1 to 25 wt. % claim 1 , of the adsorbent claim 1 , based on the total weight of the mixture of step (d) claim 1 , is added to the mixture of step (b) or step (c) claim 1 , if present.6. The method according to claim 1 , wherein when step (c) and step (e) are present claim 1 , in step (e) the mixture of step (c) or step (d) claim 1 , if present claim 1 , is cooled to a temperature of 30 to 125° C.7. The method according to claim 1 , wherein in step (g) the mixture of step (b) or step (c) claim 1 , if present claim 1 , or the mixture of step (e) claim 1 , if step (d) is not present claim 1 , or step (f) claim 1 , if present claim 1 , or the solution obtained in step (i) claim 1 , if present claim 1 , is cooled to a temperature of −10° C. to below room temperature.8. The method according to claim 1 , wherein the drying of the crystallized 4-hydroxyacetophenone in step (1) ...

TREATING AND PREVENTING DISEASES BY MODULATING CELL MECHANICS

Described are methods of treating or preventing a disease in a subject treatable by modulating cell mechanics. The method includes administering to a subject having or at risk for such a disease a pharmaceutical composition. comprising an agent selected from the group comprising a salt, solvate, or stereoisomer of compound (VIII) or its derivatives or a mixture of their constituents, where the compound has the formula: 2. The method of wherein myosin II is activated in the subject compared to a reference subject that has not been administered the effective amount of compound (V).3. The method of claim 1 , wherein the method of administering is systemic delivery selected from the group consisting of oral claim 1 , parenteral claim 1 , intranasal claim 1 , sublingual claim 1 , rectal claim 1 , and transdermal administration.4. The method of claim 1 , further comprising the step of administering a bioactive agent.6. The method of claim 4 , wherein the bioactive agent is a chemotherapy agent.7. The method of wherein the subject has a disease that is treated or prevented by modulating the cell mechanics of the subject.8. The method of wherein the disease is cancer.9. The method of wherein the cancer is pancreas or kidney cancer.12. The method of wherein myosin II is activated in the subject compared to a reference subject that has not been administered the effective amount of compound (VIII).13. The method of claim 11 , wherein the method of administering is systemic delivery selected from the group consisting of oral claim 11 , parenteral claim 11 , intranasal claim 11 , sublingual claim 11 , rectal claim 11 , and transdermal administration.14. The method of claim 11 , further comprising the step of administering a bioactive agent.16. The method of claim 14 , wherein the bioactive agent is a chemotherapy agent.17. The method of wherein the subject has a disease that is treated or prevented by modulating the cell mechanics of the subject.18. The method of wherein the ...

Antihypertensive polyol compound and derivative thereof

The present invention provides a compound as represented by formula I, or a pharmaceutically acceptable salt or ester, a prodrug, an optical isomer, a stereoisomer, or a solvate thereof. The compound provided by the present invention can be used for preparing drugs for preventing or treating hypertension, or hypertension-related diseases, or pulmonary hypertension, or pulmonary hypertension-related diseases. The compound provided by the present invention has a different mechanism from existing drugs for treating hypertension and pulmonary hypertension, thereby laying a new material foundation for the development of drugs for treating hypertension and pulmonary hypertension.

4-Acylaralkylphenols and Derivatives Thereof

4-Aralkylphenols and derivatives thereof expressed by general formulas (6) and (7) are useful for producing trisphenols. This application is a divisional of U.S. patent application Ser. No. 13/321,535, filed Jan. 13, 2012, and claims the benefits thereof under U.S.C. §121 or §365(c), which is the U.S. National Phase under 35 U.S.C. §371 of International Application PCT/JP2010/058476, filed May 19, 2010, which claims priority to Japanese Patent Application Nos. 2009-121169, filed May 19, 2009 and 2009-121170, filed May 19, 2009, each disclosure of which is herein incorporated by reference in its entirety. The International Application was published under PCT Article 21(2) in the language other than English.1. Field of the InventionThe present invention relates to a method for producing with ease at high yield and high purity in industrial settings trisphenols, which are useful as materials for polymer compounds such as epoxy resins, polycarbonate resins or the like or as materials or additives for photoresists. It also relates to a new 4-acylaralkylphenol derivative having a bisphenyl molecular skeleton with the acyl group in one phenyl ring and the hydroxyl group or acyloxy group in the other phenyl ring. Such compound is useful as various reactive materials having the effect of improving heat resistance, etc., especially as intermediate materials for generating trisphenols used as materials for polymer compounds such as polycarbonate resins or the like or as materials for photoresists, etc., through reaction with phenols.2. Description of the Related ArtAmong trisphenols, especially trisphenols other than of the trisphenol methane type, 1-[1,1-bis(4-hydroxyphenyl)ethyl]-4-[1-methyl-1-(4-hydroxyphenyl)ethyl]benzene is known. These trisphenols are favorably used as materials for polymer compounds such as epoxy resins, polycarbonate resins or the like or as materials or additives for photoresists, etc. These trisphenols are known to be obtained by reacting ...

PROCESS FOR THE PREPARATION OF A PHENYLINDAN COMPOUND

The present invention refers to a process for producing 5-[4-(2-hydroxy-2-methyl)-1-oxo-prop-1-yl]-3-[4-(2-hydroxy-2-methyl)-1-oxo-prop-1-yl-phenyl]-2,3-dihydro-1,1,3-trimethyl-1H-indene (dimer isomer 5) that comprises the synthesis from cumene and dimerization of 2-methyl-1-(4-(prop-1-en-2-yl)phenyl)propan-1-one in the presence of acid catalysts. 110-. (canceled)12. The process according to claim 11 , wherein the compound of formula Ia is isobutyryl chloride.13. The process according to claim 11 , wherein claim 11 , in step i claim 11 , from 1.50 to 1.10 moles of the compound of formula la and from 1.5 to 0.1 moles of a Lewis acid per mole of cumene are used.14. The process according to claim 11 , wherein claim 11 , in step ii claim 11 , the base is an alkali metal hydroxide.15. The process according to claim 11 , wherein claim 11 , in step ii claim 11 , the acid catalyst used in the cyclization of compound IV is a Lewis acid or an inorganic acid.16. The process according to claim 11 , wherein claim 11 , in step iv claim 11 , the compound of formula VI is hydrolysed by reaction with an alkali metal alkoxide and reaction with an aqueous acid.17. The process according to claim 16 , wherein the alkali metal alkoxide is sodium methylate.181. The process according to claim claim 16 , wherein claim 16 , in step iv claim 16 , the compound of formula VI is hydrolysed by reaction with an alkali metal hydroxide.19. The process according to claim 18 , wherein the alkali metal hydroxide is NaOH 30 wt % in methanol or in water.20. The process according to claim 19 , wherein the dimer isomer 5 is obtained in solid and pure form by crystallization after completing step iv.21. The process according to claim 11 , wherein the dimer isomer 5 is obtained in solid and pure form by crystallization after completing step iv. The present invention refers to a process for producing a regioisomer of a phenylindan photoinitiator (5-[4-(2-hydroxy-2-methyl)-1-oxo-prop-1-yl]-3-[4-(2-hydroxy-2- ...

FLUORINE-CONTAINING COMPOUND, SUBSTRATE FOR PATTERN FORMATION, PHOTODEGRADABLE COUPLING AGENT, PATTERN FORMATION METHOD, AND COMPOUND

A fluorine-containing compound represented by a following general formula (1) is provided. [In the general formula (1), X represents a halogen atom or an alkoxy group, Rrepresents a branched chain or cyclic alkyl group having 3 to 10 carbon atoms, and Rand Rrepresent fluorinated alkoxy groups. n represents an integer of 0 or greater. ] 2. The fluorine-containing compound according to claim 1 , wherein Rrepresents an isopropyl group claim 1 , an isobutyl group claim 1 , or a tert-butyl group.3. The fluorine-containing compound according to claim 1 , wherein Ror Rrepresent fluorinated alkoxy groups having 5 or more carbon atoms.4. A substrate for pattern formation having a surface chemically modified with the fluorine-containing compound according to .5. A photodegradable coupling agent formed of the fluorine-containing compound according to .6. A pattern formation method for forming a pattern on a work surface of an object claim 1 , the pattern formation method comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'chemically modifying the work surface using the fluorine-containing compound according to ;'}generating a latent image formed of a hydrophilic region and a water repellent region by irradiating the chemically modified work surface with light having a predetermined pattern; anddisposing a pattern formation material in the hydrophilic region or the water repellent region.7. A pattern formation method for forming a circuit pattern for an electronic device on a substrate having flexibility claim 1 , the pattern formation method comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'chemically modifying an entire surface or a specific region of the substrate using the fluorine-containing compound according to ;'}generating a latent image of the circuit pattern due to a difference in hydrophilicity and water repellency on the chemically modified surface of the substrate by irradiating with light energy having a distribution corresponding to the ...

Process for Preparing N-(4-Cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic Acid Ethyl Ester

This invention relates to novel processes for synthesizing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester and to the compound of formula I below and other intermediates that are used in such processes.

Multifunctional cytoprotectant for treatment of pathogenic processes mediated by oxidative stress and toxic electrophiles

Methods, filters and compositions are disclosed for treating toxicity due to oxidative stress and toxic electrophiles.

OPHTHALMIC LENS MATERIAL AND OPHTHALMIC LENS OF SUCH MATERIAL

A wetness-retaining ophthalmic lens material comprises an organic monomer, a cross-linking agent, an initiator, a salt, and a solvent. The salt dissolves in the water dissociates a plurality of anions and cations, which bind to water molecules and retard the evaporation of the water molecules, the ophthalmic lens material thus can keep wet for a long time. An ophthalmic lens made of the ophthalmic lens material is also provided. 1. An ophthalmic lens material comprising:an organic monomer;a cross-linking agent;an initiator;a salt; anda solvent comprising water.2. The ophthalmic lens material of claim 1 , wherein the organic monomer has a mass percentage of about 32% to about 81% of the total mass of the ophthalmic lens material claim 1 , the cross-linking agent has a mass percentage of about 0.08% to about 14.6% of the total mass of the ophthalmic lens material claim 1 , the initiator has a mass percentage of about 0.05% to about 12.1% of the total mass of the ophthalmic lens material claim 1 , the salt has a mass percentage of about 3% to about 21.5% of the total mass of the ophthalmic lens material claim 1 , and the solvent has a mass percentage of about 5.5% to about 51% of the total mass of the ophthalmic lens material.3. The ophthalmic lens material of claim 1 , wherein the organic monomer comprises hydrophilic monomer claim 1 , the hydrophilic monomer is selected from a group consisting of 2-hydroxyethylmethacrylate claim 1 , methyl methacrylate claim 1 , N claim 1 ,N-dimethyacrylamide claim 1 , glycidyl methacrylate claim 1 , N-vinyl-2-pyrrolidone claim 1 , and any combination thereof.4. The ophthalmic lens material of claim 3 , wherein the organic monomer further comprises an organic silicon monomer claim 3 , the organic silicon monomer is selected from a group consisting of 3-(methacryloyloxy)propyltris(trimethylsiloxy)silane claim 3 , poly(dimethylsiloxane) claim 3 , and any combination thereof.5. The ophthalmic lens material of claim 1 , wherein the cross ...

COMPOUNDS HAVING AGONISTIC EFFECT AGAINST GPR84, PREPARATION METHOD FOR COMPOUNDS AND USE OF COMPOUNDS

The present invention relates to a class of compounds represented by the formula I, or pharmaceutically acceptable salts thereof, methods for their preparation, and application as small molecule tools that function as GPR84 agonists, and their use in preparing a medicament for the treatment of septicemia. 3. A compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein claim 1 ,{'sub': 1', '1a', '5a, 'Ris R, wherein Ris methyl, isopropyl, 3-4 membered cycloalkyl, unsubstituted phenyl, cyano, hydroxy, phenyl substituted with C1-C4 alkyl, methoxyphenyl, or fluorophenyl;'}{'sub': '2', 'Ris hydroxy;'}subscript n is an integer selected from 0-14;T, W and Y are each independently O, N or C;{'sub': '3', 'Ris absent or is hydrogen, benzyl or C1-C3 alkyl;'}{'sub': '4', 'Ris absent or is hydrogen or C1-C3 alkyl;'}{'sub': '2', 'Z is —OH, —NH, ═O, ═S or C1-C6 alkylcarbonyl.'}7. A pharmaceutical composition comprising a therapeutically effective amount of one or more selected from the group consisting of the compound or pharmaceutically acceptable salts thereof according to claim 1 , and one or more pharmaceutically acceptable carriers.8. A use of the compound or pharmaceutically acceptable salts thereof according to claim 1 , in preparing a medicament for the treatment of septicemia. The present invention relates to a class of compounds having an agonistic effect against GPR84 represented by the formula I, methods for their preparation, and their use in preparing a medicament for the treatment of septicemia.G protein-coupled receptors (GPCRs) are a large family of membrane protein receptors, with 367 human gene encoding related proteins, which are almost involved in the regulation of all physiological functions of the cell. Currently, there are many known GPCRs ligands such as gases, hormones, neurotransmitters, and chemokines. In addition, it has been found that many free fatty acids (FFAs) are endogenous ligands of GPCRs. The FFAs mainly bind to free ...

ACTIVATORS OF MYOSIN II FOR MODULATING CELL MECHANICS

The present invention discloses small molecule compounds as activators of myosin II by promoting its assembly and recruitment to contractile structures in the cell and methods of using such compounds. These compounds are useful to modulate cell and tissue mechanics. This class of molecules, which affect cell mechanics either by activating the contractile system of the cell or modulating cytokinesis, will be used for therapeutic and tissue engineering applications. 2. The method of claim 1 , wherein the method of administering is systemic delivery selected from the group consisting of oral claim 1 , parenteral claim 1 , intranasal claim 1 , sublingual claim 1 , rectal claim 1 , and transdermal administration.4. The method of claim 3 , wherein the method of administering is systemic delivery selected from the group consisting of oral claim 3 , parenteral claim 3 , intranasal claim 3 , sublingual claim 3 , rectal claim 3 , and transdermal administration.6. The method of claim 5 , wherein the method of administering is systemic delivery selected from the group consisting of oral claim 5 , parenteral claim 5 , intranasal claim 5 , sublingual claim 5 , rectal claim 5 , and transdermal administration.8. The method of claim 7 , wherein the method of administering is systemic delivery selected from the group consisting of oral claim 7 , parenteral claim 7 , intranasal claim 7 , sublingual claim 7 , rectal claim 7 , and transdermal administration.10. The compound of claim 9 , wherein the compound is administered by systemic delivery selected from the group consisting of oral claim 9 , parenteral claim 9 , intranasal claim 9 , sublingual claim 9 , rectal claim 9 , and transdermal administration.12. The compound of claim 11 , wherein the compound is administered by systemic delivery selected from the group consisting of oral claim 11 , parenteral claim 11 , intranasal claim 11 , sublingual claim 11 , rectal claim 11 , and transdermal administration.14. The compound of claim 13 ...

Processes for preparing antiviral compounds

The present disclosure provides processes for the preparation of a compound of formula: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.

TREATING AND PREVENTING DISEASES BY MODULATING CELL MECHANICS

Described are methods of treating or preventing a disease in a subject treatable by modulating cell mechanics. The method includes administering to a subject having or at risk for such a disease a pharmaceutical composition. comprising an agent selected from the group comprising a salt, solvate, or stereoisomer of compound (VIII) or its derivatives or a mixture of their constituents, where the compound has the formula: 110.-. (canceled)12. The method of wherein myosin II is activated in the subject compared to a reference subject that has not been administered the effective amount of compound (VIII).13. The method of claim 11 , wherein the method of administering is systemic delivery selected from the group consisting of oral claim 11 , parenteral claim 11 , intranasal claim 11 , sublingual claim 11 , rectal claim 11 , and transdermal administration.14. The method of claim 11 , further comprising the step of administering a bioactive agent.16. The method of claim 14 , wherein the bioactive agent is a chemotherapy agent.17. The method of wherein the subject has a disease that is treated or prevented by modulating the cell mechanics of the subject.18. The method of wherein the disease is cancer.19. The method of wherein the cancer is pancreas or kidney cancer.2031.-. (canceled)33. An in vivo claim 18 , large-scale and high-throughput screening method for identifying cell mechanical modulator claim 18 , the screening method comprising the steps of: (a) obtaining cells and placing the cells on multiple-well substrate plates for cytokinesis; (b) contacting the cells on multiple-well substrate plates with compound candidates; and (c) monitoring and analyzing the cytokinesis and the growth of the cells.34Dictyostelium discoideum. The screening method of claim 33 , wherein the cells are from strains.35Dictyostelium discoideum. The screening method of claim 34 , wherein strains comprise wild type and mutants.36. (canceled)37. The method of claim 32 , further comprising the ...

AROMA COMPOSITION

Suggested is an aroma composition comprising (a) hesperetin dihydrochalcone or a salt thereof, and (b) high fructose corn syrup (HFCS), providing a high degree of sweetness, but low caloric input. 2. The composition of claim 1 , further comprising:(c) a sweetener or sweetness enhancer selected from the group consisting of steviosides, fructose, glucose, saccharin, sugar alcohols, cyclamate, neohesperetin dihydrochalcone, erythritol, phloretin and a mixture thereof.3. The composition of claim 2 , wherein said sweetener is a stevioside.4. The composition of claim 3 , wherein said stevioside is rebaudioside A.5. The composition of claim 1 , comprising components (a) and (b) in a weight ratio of from about 0.500:99.500 to about 0.0001:99.9999.6. The composition of claim 2 , comprising components (a+b) and (c) in a weight ratio of from about 99.99950:0.00050 to about 25:75.7. The composition of exhibiting sugar content in the range of from 0° Brix to 13° Brix.8. An oral composition comprising the aroma composition of .9. The composition of being a beverage10. The composition of being a soft drink.11. The composition of being a protein shake.12. The composition of comprising said aroma composition in an amount of from 0.1 to about 30 wt.-percent.13. A method for making an oral composition comprising:(i) providing a base for the oral composition;{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(ii) providing the aroma composition of ;'}(iii) blending the base and the aroma composition together; and(iv) optionally, adding carbonic acid.14. (canceled)15. (canceled)16. A method for sweetening an oral composition comprising adding the aroma composition of to an oral composition.17. The method of claim 16 , wherein the oral composition is a beverage with high sweetness and reduced calories.18. The method of claim 13 , wherein the oral composition is a beverage with high sweetness and reduced calories. The present invention relates to the area of oral compositions, in ...

PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS

The present disclosure provides processes for the preparation of a compound of formula: 13.-. (canceled)5. The method of claim 4 , wherein X is bromo and Y is bromo.6. The method of claim 4 , wherein the reaction conditions comprise a solvent selected from the group consisting of dichloromethane claim 4 , 2-methyltetrahydrofuran claim 4 , tetrahydrofuran claim 4 , isopropyl acetate claim 4 , ethyl acetate claim 4 , tert-butyl methyl ether claim 4 , cyclopentyl methyl ether claim 4 , dimethylformamide claim 4 , acetone claim 4 , methyl ethyl ketone claim 4 , and methyl isobutyl ketone.7. The method of claim 4 , wherein the reaction conditions comprise a temperature of from about 10° C. to about 60° C. or from about 10° C. to about 30° C.8. The method of claim 4 , wherein the reaction conditions comprise a base.9. The method of claim 8 , wherein the base is a phosphate salt or a carbonate salt.10. The method of claim 4 , comprising contacting a compound of formula (I) claim 4 , stereoisomer thereof claim 4 , or mixture of stereoisomers thereof claim 4 , with a salt of compound of formula (J).11. The method of claim 10 , wherein the salt of the compound of formula (J) is a potassium claim 10 , a sodium claim 10 , or a cesium salt.13. The method of claim 12 , wherein the salt of a compound of formula (H) is a potassium claim 12 , a sodium claim 12 , or a cesium salt. This application is a continuation of U.S. application Ser. No. 16/404,550, filed May 6, 2019, which is a divisional of U.S. application Ser. No. 15/847,803, filed Dec. 19, 2017, now abandoned, which is a continuation of U.S. application Ser. No. 15/582,224, filed Apr. 28, 2017, now U.S. Pat. No. 9,890,134, which is a continuation of U.S. application Ser. No. 14/733,139, filed Jun. 8, 2015, now U.S. Pat. No. 9,670,187, which claims priority to and the benefit of U.S. Provisional Application No. 62/010,813, filed Jun. 11, 2014, all of which are hereby incorporated by reference in their entireties.The present ...

Surfactant photoinitiator

Molecular complex compounds as photoinitiators

Process for epoxidising prochiral olefins and a catalyst therefor and intermediates for making the catalyst

Process for producing alpha-hydroxyketones

Method of epoxidation of prochiral olefin

FIELD: chemical technology. SUBSTANCE: invention relates to method of epoxidation of prochiral olefin. Method involves interaction of prochiral olefin with oxygen source in the presence of salt catalyst. Epoxidation is carried out in the presence of isoquinoline N-oxide as ligand donor. Compound of formulas (IB) or (II) characterized by claim 2 of the invention claim are used as catalyst. Except for, invention proposes variant of method where interaction of prochiral olefin with oxygen source is carried out in the presence of compound of the formula (II) as salt catalyst and ligand source donating electron. EFFECT: improved method of epoxidation. 7 cl, 21 ex С9ЭЗУОСС ПЧ сэ (19) РОССИЙСКОЕ АГЕНТСТВО ПО ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ ВИ” 2 204 562 ' (51) МПК” 13) С2 13/00//(С 07 О 493/04, 309:00, 303:00) С 070 493/04, 301/12, С 07 Е 12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ РОССИЙСКОЙ ФЕДЕРАЦИИ (21), (22) Заявка: 96117466/04 , 01.02.1995 (24) Дата начала действия патента: 01.02.1995 (30) Приоритет: 04.02.1994 СВ 9402213.4 04.02.1994 СВ 9402194.6 04.02.1994 СВ 9402200.1 15.06.1994 СВ 9411937.7 15.06.1994 СВ 9411936.9 15.06.1994 СВ 9411957.5 (43) Дата публикации заявки: 27.12.1998 (46) Дата публикации: 20.05.2003 (56) Ссылки: ММО 94/03271 А, 17.02.1994. МО 91/14694 А, 03.10.1994. ЗЦ 588527 А, 01.02.1978. ОЕ 4238076 С1, 16.09.1993. (85) Дата перевода заявки РСТ на национальную фазу: 04.09.1996 (86) Заявка РСТ: ЕР 95/00370 (01.02.1995) (87) Публикация РСТ: М/О 95/21172 (10.08.1995) (98) Адрес для переписки: 129010, Москва, ул. Б.Спасская, 25, стр.3, ООО "Юридическая фирма Городисский и Партнеры", пат.пов. Е.В.Томской, рег.№ 106 (71) Заявитель: СМИТКЛАИН БИЧАМ ПЛС (СВ) (72) Изобретатель: БЕЛЛ Дэвид (СВ), ФИННЕЙ Франциска (СВ), АТТРИЛЛ Робин Патрик (СВ), МИЛЛЕР Дэвид (СВ), ТЕРНЕР Джиллиан (СВ) (73) Патентообладатель: СМИТКЛАЙН БИЧАМ ПЛС (СВ) (74) Патентный поверенный: Томская Елена Владимировна (54) СПОСОБ ЭПОКСИДИРОВАНИЯ ПРОХИРАЛЬНОГО ОЛЕФИНА (57) Изобретение относится к способу ...

페닐인단 광개시제의 제조 방법

본 발명은 이소부티릴 할라이드를 갖는 4-포지션에서 큐멘의 아실화 후, 벤질 할로겐화 및 생성물의 이량체화(고리화)를 포함하는 5-[4-(2-하이드록시-2-메틸)-1-옥소-프로프-1-닐]-3-[4-(2-하이드록시-2-메틸)-1-옥소-프로프-1-닐-페닐]-2,3-디하이드로-1,1,3-트리메틸-1H-인덴 (이량체 이성질체 5)를 제조하는 방법에 관한 것이다.

The method of the composition and treatment Neurodegenerative conditions of polyhydroxylated benzophenone

本发明涉及多羟基化二苯甲酮化合物，所述化合物可用于治疗神经退行性疾病、神经疾病、精神疾病、以及认知疾病，特别是与HDAC1脱乙酰酶活性缺陷相关的那些疾病。

A kind of production 1173 and 184 circulation technology of photoinitiator

本发明涉及一种光引发剂1173/184含氯化钠工艺废水循环使用技术。一方面光引发剂1173/184制备过程中产生的高盐废水即得到了有效处理，解决了巨大的环境压力，又可以变废为宝，转化成反应原料，资源循环利用；另一方面又较传统的氯碱工业，简化了氯气及氢氧化钠的后处理流程，达到了资源循环再生的目的，环境友好符合绿色化学的要求，同时还降低了生产成本。

Patent DE2560549C2

Synthetic methods for prenylated chalcones and pyranochalcones

The present inventors have invented a simple and effective method for synthesizing natural prenyl chalcone and pyran chalcone compound 1-9 using Claisen-Schmidt condensation as a main step. In addition, the anti-inflammatory effects of the synthesized compounds were evaluated in RAW 264.7 macrophages stimulated with glutathione peroxidase. As a result, chalcone compounds having a phenyl group at the ring A (acetophenone portion) did not exhibit a weak inhibition or inhibition against nitric oxide production, whereas chalcone (5, 6, 8 and 9) Showed normal or good activity, and no cytotoxicity.

New photoinitiators

The invention relates to novel photoinitators of formulae (I), (II), (III), (IV), (V) and (VI) wherein R1 and R2 are each independently of the other C1-C8alkyl; C1-C4alkyl substituted by OH, C1-C4alkoxy, -COO(C1-C8alkyl), (C1-C4alkyl)-COO-, -CN, benzyl, phenyl or by -N(R15)(R16); C3-C6alkerlyl, benzyl, -CH2-C6H4-(C1-C4alkyl) or phenyl; or R1 and R2 together are unbrarched or branched C2-C9alkylene or C3-C6-oxa- or -aza­alkylene; R3, R4, R5 and R6 are each independently of the others hydrogen, C1-C8alkyl, C3-C6alkenyl, benzyl, -CH2-C6H4-(C1-C4alkyl) or phenyl; R3 and R4 together and/or R5 and R6 together are unbranched or branched C2-C9alkylene; A is CI, Br, -O-R9, -N(R11)(R12) or -S-R18, A' is -O-, -NH- or -NR11-; A' is CI, Br, -O-R9, -N(R11)(R12) or -S-R18 or hydrogen, X is -O-R10 or -N(R13)(R14), n is an integer from 1 to 10, preferably an integer from 1 to 4, especially 1, 2 or 3; R7 is a linker; R8 is a bivalent C2-C3alkylele radical.

New derivatives of an aminoketone

내용 없음. No content.

Derivatives of &&&-substituted arylacetic acids and pharmaceutical composition

Использование: в медицине для подавления действия ацетилтрасферазы карнитина при предотвращении поражения ишемической ткани. Сущность изобретения: продукт: производные a - замещенных арилуксусных кислот общей формулы I, приведенной в тексте описания, где R 1 , R 2 , R' 2 , A, n, B, и Q имеют соответствующие значения. Дозы соединения формулы 1 или его соли, при введении через рот составляют от 1 до 2000 мг в день, желательно от 25 до 500 мг в виде разовой дозы или дробными дозами. 21 з. п. ф-лы, 3 табл. $5096%$0с ПЧ Го РОССИЙСКОЕ АГЕНТСТВО ПО ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (19) (51) МПК ВИ” 2 059 603 ' С 07С 59/68, 59/90, 69/736, 13) СЛ 235/34, С 07 0 275/00, 317/00, 333/24, 333/32, А 61 К 31/185, 31/38, 31/44 12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ РОССИЙСКОЙ ФЕДЕРАЦИИ (21), (22) Заявка: 5011784/04, 31.01.1992 (30) Приоритет: 09.05.1991 1$ 698014 (46) Дата публикации: 10.05.1996 (71) Заявитель: Хоффманн-Ля Рош АГ (СН) (72) Изобретатель: Роберт Вильям Гитри[Ц$], Джон Гуилфелд Маллин[Ц$], Гай Филлип Хетерс[ СВ], Алан Джон Хиггинс СВ], Рональд Эндрю Ле Майе[Ц$], Давид Френсис Каченски[У $], Ричард Вайтмен Керстед[ $], Джефферсон Райт Тилли[Ц$] (73) Патентообладатель: Хоффманн-Ля Рош АГ (СН) (54) ПРОИЗВОДНЫЕ о -ЗАМЕЩЕННЫХ АРИЛУКСУСНЫХ КИСЛОТ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (57) Реферат: Использование: в медицине для подавления действия ацетилтрасферазы карнитина при предотвращении поражения ишемической ткани. Сущность изобретения: продукт: производные а - замещенных арилуксусных кислот общей формулы |, приведенной в тексте описания, где Кл, В>, К'2, А, п, В, и О имеют соответствующие значения. Дозы соединения формулы 1 или его соли, при введении через рот составляют от 1 до 2000 мг в день, желательно от 25 до 500 мг в виде разовой дозы или дробными дозами. 21 з. п. ф-лы, 3 табл. 2059603 С1 КО

Process for preparing 22arylalkanic ester

Process for Epoxidising Prochiral Olenfins and a Catalyst Therefor and Intermediates for Making the Catalyst

프로키랄 올레핀을 살렌 촉매 및 전자 공여 리간드 공급원의 존재하에 산소 공급원과 반응시키는 것을 포함하는 프로키랄 올레핀의 에난티오머 선택적 에폭시드화 방법에 있어서, 상기 공여체 리간드가 이소퀴놀린 N-옥시드 또는 공여체 리간드 활성을 갖고 용해도 특성이 이소퀴놀린 N-옥시드와 실질적으로 동일한 화합물일 것을 특징으로 하는 방법 및 이 방법에 사용되는 화합물에 관한 것이다. 또한, 본 발명은 다음 화학식의 촉매(III) 및 그의 제조용 중간체에 관한 것이다. 식 중, M은 전이 금속 이온이고, A는 필요에 따라 카운터 이온이고, B, B', E 및 E'는 독립적으로 수소, 아릴, C 1-6 알킬, 실릴 또는 아릴-C 1-6 알킬(여기서, 아릴 또는 알킬 부분은 임으로 치환될 수 있음)이거나, 또는 B' 및 B 또는 E' 및 E는 함께 C 2-6 폴리메틸렌 고리를 형성하며, 단 * 표시된 탄소들 중 하나만이 키랄 중심이고, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 및 R 10 은 독립적으로 수소, 알킬 또는 알콕시이다.

Process for the preparation of a phenylindan photoinitiator

本发明涉及一种制备(5‐[4‐(2‐羟基‐2‐甲基)‐1‐氧代‐丙‐1‐基]‐3‐[4‐(2‐羟基‐2‐甲基)‐1‐氧代‐丙‐1‐基‐苯基]‐2,3‐二氢‐1,1,3‐三甲基‐1H‐茚(二聚物异构体5)的方法，所述方法包括用异丁酰卤化物使枯烯在4‐位发生酰化，然后使得到的产物进行芐基卤化反应和二聚合反应(环化反应)。

Method for preparing Licochalcones

본 발명은 리코칼콘계 화합물의 제조방법에 관한 것이다. 보다 상세하게는, 감초에서 분리 추출한 약리학적 활성이 우수한 리코칼콘계 화합물을 화학적으로 합성하고, 염증성 매개 질병 치료 및 예방에 적용할 수 있는 리코칼콘계 화합물의 제조방법에 관한 것이다. 리코칼콘, 감초, 유기합성, 염증성 매개 질병

Novel benzyl alcohol derivative and its preparation

Manufacture of 1-hydroxyketone

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

Process for preparing benzofurans

本发明提供一种用于制备式(I)的化合物的方法，其中R 1 ，R 2 ，R 3 ，R 4 ，X和Y如说明书中所述。这些化合物在药物比如决奈达隆的合成中可以例如是有用的中间体。所述方法的中间体步骤包括根据(II)和(III)的式。

Photopolymerizing composition

Process for preparing benzofurans

A pharmeceutical composition for preventing or treating neurodegenerative disease comprising extract of Cynanchum paniculatum kitagawa or compound derived therefrom as active ingredient

본 발명은 신경세포보호효과를 나타내는 화합물(4-O-methyl ether gallacetophenone 또는 2,3-Dihydroxy-4-methoxyacetophenone) 또는 이의 약학적으로 허용되는 염, 상기 화합물을 포함하는 서장경 추출물 또는 상기 화합물 또는 이의 약학적으로 허용되는 염을 포함하는 신경세포보호용 조성물, 상기 화합물을 포함하는 서장경 추출물 또는 상기 화합물 또는 이의 약학적으로 허용되는 염을 포함하는 퇴행성 신경계 질환의 예방 또는 치료용 조성물 및 상기 화합물을 포함하는 서장경 추출물 또는 상기 화합물 또는 이의 약학적으로 허용되는 염을 포함하는 퇴행성 신경계 질환의 예방 또는 개선용 식품조성물에 관한 것이다. 본 발명의 서장경 추출물 또는 화합물은 오랫동안 천연약재로서 사용되어온 천연물에서 유래되어 부작용이 없으면서도, 신경세포에 대한 보호효과를 나타내어 치매 등의 신경계 질환의 치료제로 사용될 수 있으므로, 치매를 비롯한 다양한 신경계 질환의 보다 안전한 치료에 널리 활용될 수 있을 것이다.

Method of obtaining 2-alkylindan

Method for preparing binaphthol aldehyde derivatives and intermediate thereof

본 발명은 하기 화학식 3의 화합물을 환원시켜서 하기 화학식 2의 화합물을 얻는 단계 및 상기 단계에서 얻은 화학식 2의 화합물을 산화시키는 단계를 포함하는 하기 화학식 1의 화합물의 제조방법 및 상기 방법을 포함하는 바이나프톨 알데히드 유도체의 제조방법에 관한 것이다. The present invention provides a method for preparing a compound of Formula 1 and a method comprising the step of reducing the compound of Formula 3 to obtain a compound of Formula 2 and oxidizing the compound of Formula 2 obtained in the step: A method for preparing a naphthol aldehyde derivative. [반응식 1] Scheme 1 키랄 합성, 아미노산, 아미노 알코올, 바이나프톨 Chiral synthesis, amino acid, amino alcohol, binaphthol

Molecular complex compounds as photoinitiators

Molecular complex compounds (I) of a mono-, bis- or tris-acylphosphine oxide compound (II) with an alpha -hydroxyketone compound (III) are new. Also claimed are (a) photopolymerisable compositions containing ethylenically unsaturated polymerisable compound(s) and (I) as photoinitiator; (b) a method for photopolymerisation of such compositions; (c) substrates coated with the composition; and (d) the photographic production of reliefs by selective exposure of the coated substrate and removing the unexposed areas with a solvent.

Process for the production of optically active gamma-hydroxyketones

Process for preparing benzofurans

There is provided a process for the preparation of a compound of formula (I), wherein R1, R2, R3, R4, X and Y are as described in the description. Such compounds may, for example, be useful intermediates in the synthesis of drugs such as Dronedarone. Intermediate steps of the process comprise formulae according to (II) and (III).

Manufacture of intermediate for leukotriene antagonist

NOVEL BENZYL ALCOHOL DERIVATIVE AND PROCESS FOR PREPARING THE SAME

Compounds capable of inhibiting zinc ion metalloproteinases

The invention has disclosed 1,2,3-trihydroxy benzene and its derivatives or pharmaceutically acceptable salts of formula I for zinc ion metal-protease inhibition. These compounds are used for selective depressants of zinc ion metal-proteases such as MT1-MMP,gelatinase A, B and collagenase, matrilysins, metal-elastase or stromelysin-1. These depressants can be used to adjust many physiological or pathology courses which are concerned with MMPs, ADAMs, ADAM-TS such as vessel rebirth, wound healing, organ transplantation, fecundation course and reactivation capability, bone rebuilding and ache. They are used for treating cancer, cardiovascular diseases, arthritis, periodontal disease, multiple sclerosis, inflammation, adenomyosis, cornea ulcer, bacterial meningitis, diabetic syndrome, kidney diseases, nerve retrogression diseases, AIDS, bleb, anaphylaxis, adenomyosis, osteoporosis, asthma and so on. These blocking agents can be used for antisenescence, antibiosis, commercial manufacture addition agents of cell epimatrix, collagen product, cosmetics and make-up preparation. They can used for animals and other living bodies.

Intermediates useful for the preparation of antihistaminic piperidine derivatives

The present invention is related to a novel intermediates and processes which are useful in the preparation of certain antihistaminic piperidine derivatives of the formula wherein W represents —C(═O)— or —CH(OH)—; R 1 represents hydrogen or hydroxy; R 2 represents hydrogen; R 1 and R 2 taken together form a second bond between the carbon atoms bearing R 1 and R 2 ; n is an integer of from 1 to 5; m is an integer 0 or 1; R 3 is —COOH or —COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A is hydrogen or hydroxy; and pharmaceutically acceptable salts and individual optical isomers thereof, with the proviso that where R 1 and R 2 are taken together to form a second bond between the carbon atoms bearing R 1 and R 2 or where R 1 represented hydroxy, m is an integer 0.

NEW FLUOROACYLRESORCINS SUBSTITUTED AND MEDICINES, COSMETICS AND PESTICIDES CONTAINING THEM

L'invention a pour objet des nouvelles fluoroacylrésorcines. Ces nouveaux composes répondent à la formule générale I : The subject of the invention is novel fluoroacylresorcins. These new compounds correspond to the general formula I:

PROCESS FOR THE PREPARATION OF 2-ARYLALCANOIC ACIDS AND THEIR SALTS AND ESTERS

L'addition concerne la préparation de 2-aryl-(alcanoates en C3 à C6 ) suivant le brevet principal. Un énol-éther d'une arylalkylcétone est amené à réagir avec un sel de thallium trivalent dans un solvant organique. Les ions T1**+++ peuvent être régénérés par addition d'un péracide et d'une forme réactive de Mu, Ru, Co, Ir, Hf, Os ou Nb pour oxyder les ions T1**+ en ions T1**+++. L'ester intermédiaire est ensuite transformé en acide 2-aryl-(alcanoïaque en C3 à C6 ) correspondant ou en sel de cet acide. Application à la préparation de médicaments acides tels que ibuprofène, flurbiprofène, fénoprofène, naproxène, etc. The addition relates to the preparation of 2-aryl- (C3-C6 alkanoates) according to the main patent. An enol ether of an arylalkyl ketone is reacted with a trivalent thallium salt in an organic solvent. T1 ** +++ ions can be regenerated by adding a peracid and a reactive form of Mu, Ru, Co, Ir, Hf, Os or Nb to oxidize T1 ** + ions to T1 ** ions +++. The intermediate ester is then converted to the corresponding 2-aryl- (C3-C6 alkanoic) acid or a salt thereof. Application to the preparation of acidic medicaments such as ibuprofen, flurbiprofen, fenoprofen, naproxen, etc.

Substd acetophenones - with selective herbicidal activity

Title cpds. are of formula: where R1 and R3 are H, OH, -OMe, -OEt, acetoxy, halogenated acetoxy, phenoxy, 2,4-dechlorophenoxy, 4-chloro-2-methylphenoxy, -O2C.NH2, -O.CS.NH2, -S.CO.NH2, NO2, (substd.) NH2, heterocycle amino, halogen, provided that both are not H; R2, R4 are H, halogen, NO2, -CH2Cl, provided that both are not H; X and Z are H, halogen; Y is H, halogen, opt. substd. Me; when R1 or R3 is halogen, R2 and R4 are H, NO2 or -CH2Cl; R2 and R4 must not both be H and R1, R2, R3, R4 must not all be identical.

NOVEL BENZYL ALCOHOL DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

Antidiabetic and/or hypolipaemic aromatic cpds. - e.g. 4'-(1-hydroxy-2,2-dimethylpropyl)-acetophenone

Cpds. of formula (I) are new: (where R3 is H, F, Cl, or Br; and (i) R1 is t-butyl and R2 is H, 1-4C alkyl except t-butyl, 3-5C alkenyl or a gp. (II): R4 is H,F,Cl,Br or CF3; and in this case -C(AB)- is a gp. (III): -CHOH- (II) and -C(DE)- is (IV), (V) or (VI); -CO- (IV), n is 0 or 1; X is -CH2 or -C(CH3)2, or -C(AB)- is a gp. (VII) - CH(OCOR6)- (VII); R6 is 1-3C alkyl, and -C(DE)- is (IV); R2 being CH3; or -C(AB)- is (IV) and -C(DE)- is (III) or (VII); or -C(AB)- is (VI) and -C(DE)- is (III), (IV) or (V) R2 being (II) when -C(DE)- is (III) and 1-4C alkyl, (except. t-butyl) when -C(DE)- is (IV); or (ii) R1 is 3-6C cycloalkyl and R2 is 1-4C alkyl and in this case -C(AB)- is (III) and -C-(DE)- is (IV) or (VI), or -C(AB)- is (VI) and -C(DE- is (IV); or (iii) R1 is (II) Nand R2 is H, 1-4C alkyl, 3-5C alkenyl or (II), and in this case -C-(AB)- is (III) and -C(DE)-is (IV) or (VI), or -C(AB)- is (IV and -C(DE)-2 is (III), R2 being t-Bu or (II), or -C(AB)- is (VI) and -C(DE)- is (III), R2 being t-Bu or (II), or -C(AB)- is (VII) and -C(DE)- is (IV), R2 being t-Bu). Certain (I) are hypolipaemic, others are antidiabetics for adults; and others are juvenile antidiabetics.

Patent FR2361329B1

AROMATIC PERFLUOROALCANE MONOMER

Monomère perfluoroalcane aromatique, utilisable pour la synthèse d'une membrane polymère pour pile à combustible du type PEM, répondant à la formule : dans laquelle: - n est compris dans un domaine de 1 à 20 ; les symboles Ar , Ar , Ar et Ar , identiques ou différents, représentent un groupe phénylène, substitué ou non substitué ; les symboles Z et Z , identiques ou différents, représentent une fonction polymérisable. Aromatic perfluoroalkane monomer, which can be used for the synthesis of a polymer membrane for a fuel cell of the PEM type, corresponding to the formula: in which: - n is in a range from 1 to 20; the symbols Ar, Ar, Ar and Ar, which are identical or different, represent a substituted or unsubstituted phenylene group; the symbols Z and Z, which are identical or different, represent a polymerizable function.

Photographic material suited for use in diffusion transfer photography

Abstract A photographic material for diffusion transfer photo-graphy containing a quinonoid compound, which is capable in reduced state and under alkaline conditions of releas-ing a photographically useful group and corresponds to one of the following general formulae : (A) (B) wherein : each of (Nuox)1 and (Nuox)2 (same or different) repre-sents an oxidized nucleophilic group, Z represents a bivalent atom or bivalent atomic group, which is electro-negative, Q together with the group Z represents a releasable photographically useful group, Y1 and Y2 together represent the necessary atoms to close a p-quinonoid ring substituted with (a) directly linked monavalent organic ring or ring system substituent(s) having aromatic character, Y3 represents the necessary atoms to close a o-quinonoid ring substituted with (a) directly linked monovalent organic ring or ring system substituent(s) having aromatic character, and each of R1 and R2 (same or different) represents hydrogen or a (substituted) hydrocarbon group, and at least one of R1, R2 and a substituent on the quinonoid ring being or carrying a ballasting group.

NEW BASIC PARA-BENZOLETHERS AND PROCESS FOR THEIR PREPARATION

Automatic dewaxer for printed fabric chains

Patent JPH0359890B2

Patent FR2183681A1

AROMATIC PERFLUOROALCANE MONOMER

Monomère perfluoroalcane aromatique, utilisable pour la synthèse d'une membrane polymère pour pile à combustible du type PEM, répondant à la formule : dans laquelle: - n est compris dans un domaine de 1 à 20 ; les symboles Ar , Ar , Ar et Ar , identiques ou différents, représentent un groupe phénylène, substitué ou non substitué ; les symboles Z et Z , identiques ou différents, représentent une fonction polymérisable. An aromatic perfluoroalkane monomer useful for the synthesis of a polymer membrane for a PEM fuel cell, having the formula: wherein: n is in a range from 1 to 20; the symbols Ar, Ar, Ar and Ar, which are identical or different, represent a substituted or unsubstituted phenylene group; the symbols Z and Z, which are identical or different, represent a polymerizable function.

Patent FR2348189B1

Patent FR2163432A1

Patent FR2534580B1

Novel hydroxyphenylketone

Process for preparing benzofurans

There is provided a process for the preparation of a compound of formula I, wherein R 1 , R 2 , R 3 , R 4 , X and Y are as described in the description via compounds of formula III.: Such compounds may, for example, be useful intermediates in the synthesis of drugs such as Dronedarone.

Fullerene derivatives, their production method and their use

Methods for controlling free radical generation by inflammatory cells

Methods, compositions and compounds for the treatment of chronic inflammatory diseases, such as inflammatory bowel disease, are described. The methods, compositions and compounds of the invention are effective to inhibit the oxidative burst pathway.

Process for producing acyloxy aromatic carboxylic acid

ABSTRACT OF THE DISCLOSURE Acyloxy aromatic carboxylic acids, e.g., 4-acetoxybenzoic acid, are prepared by oxidizing with oxygen an acyloxy aromatic ketone, e.g., 4-acetoxyacetophenone in the presence of transition metal ions as catalyst and a co-reductant. The acyloxy aromatic ketone may be prepared by acylating a hydroxy aromatic ketone, e.g., 4-hydroxyacetophenone, which has the effect of "masking" the hydroxyl group of the ketone in a manner necessary to effect the subsequent transition-metal catalyzed oxidation of the ketone to the acyloxy aromatic carboxyic acid.

Process for preparing antiviral compounds

New derivatives of an aminoketone

Naphthalene-based inhibitors of anti-apoptotic proteins

Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, or NHSO2X, wherein X is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocycle, or substituted heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.

Patent FR2163432B1

Ketoximinoether insecticides

There are now provided new specifically substituted methyl ethers of ketoximes, wherein one portion of the ketox­ ime is phenyl substituted by nitro, trifluoromethylthio, dif­ luoromethylthio, 2,2-difluoromethylenedioxy, trif­ luoromethoxy, difluoromethoxy, haloalkoxy or sulfonamido, and the other is alkyl, which may contain substituents, such as halogen, hydroxy, alkoxy, alkylthio, alkylsulfonyl, nitro, car­ balkoxy, acyl or cyano. There are also provided the method of combatting insects with these compounds and insecticidal compositions containing them and a suitable carrier.

Process for producing benzofurane derivatives

Naphthalene-based inhibitors of anti-apoptotic proteins

Benzofuran derivatives,their preparation and pharmaceutical compositions containing them

Intermediates useful for the preparation of antihistaminic piperidine derivatives

The present invention is related to a novel intermediates and processes which are useful in the preparation of certain antihistaminic piperidine derivatives of the formula wherein W represents —C(═O)— or —CH(OH)—; R 1 represents hydrogen or hydroxy; R 2 represents hydrogen; R 1 and R 2 taken together form a second bond between the carbon atoms bearing R 1 and R 2 ; n is an integer of from 1 to 5; m is an integer 0 to 1; R 3 is —COOH or —COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A is hydrogen or hydroxy; and pharmaceutically acceptable salts and individual optical isomers thereof, with the proviso that where R 1 and R 2 are taken together to form a second bond between the carbon atoms bearing R 1 and R 2 or where R 1 represented hydroxy, m is an integer 0.

PROCESS FOR THE PREPARATION OF ALCOHOL-SULFONYL-METHYL-BENZYL ALCOHOLS

New compound and its synthesis method

Extractants and method for the recovery of palladium

NOVEL EXTRACTANTS AND METHOD FOR THE RECOVERY OF PALLADIUM ABSTRACT OF THE DISCLOSURE Novel ortho alkoxy substituted phenyl oxime compounds which are useful for selectively separating and recovering palladium from aqueous compositions and mixtures containing palladium and other metals are disclosed. Also disclosed is a method of separating and purifying palladium which is present in a solution with at least one other platinum group metal by adjusting the pH of the solution to from about 0 to 5, contacting the acidified solution with an ortho alkoxy substituted phenyl oxime compared by means of solvent using solvent extractions techniques, separating the aqueous phase from the organic phase containing substantially all of the palladium in association with the oxime compound, and stripping the palladium from the association with the oxime compounds in the organic phase by extraction with an aqueous ammonia solution.

Pharmacologically active 2-and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same

PHARMACOLOGICALLY ACTIVE 2- AND 3- SUBSTITUTED (1',5'-DIARYL-3-PYRAZOLYL)-N-HYDROXYPROPANAMIDES AND METHOD FOR SYNTHESIZING THE SAME ABSTRACT 2- and 3-substituted (1',5'-diaryl-3'-pyrazolyl)-N-hydrosypropanamides, a method for their preparation, compositions containing the same and methods of their use are disclosed. The N-hydroxypropanamides are useful in alleviating inflammatory and cardiovascular disorders in mammals.

Synthetic method for licochalcone C

본 발명자들은 Al 2 O 3 를 이용한 C -프레닐화 방법, 위치선택적 보호기화 및 메틸화, 그 이후에 염기 조건 하에서 통상적인 클라이젠-슈미트 응축반응을 수행하여 리코찰콘 C를 제조하였다. 물에 의해 촉진되는 [3,3]-시그마결합 자리옮김반응은 분해 문제로 인하여 리코찰콘 C 합성에 적용할 수 없었으나, 본 발명자들은 Al 2 O 3 를 이용한 위치선택적 C -프레닐화가 리코찰콘 C를 합성하는 새로운 방법임을 밝혔다. The present inventors have made a method of C -prernylation using Al 2 O 3 , position selective protection and methylation, followed by a conventional Clagen-Schmid condensation reaction under basic conditions to produce Ricochalcone C. Although the water-promoted [3,3] -sigma binding site transfer reaction could not be applied to the synthesis of Ricochalcone C due to degradation problems, the present inventors have found that positionally selective C -prenylation using Al 2 O 3 , C as a new method to synthesize.

BENTSOFURANDERIVAT.

Process for the production of deoxy-alpha-acids

Preparation of deoxy-α-acids (deoxyhumulons) by prenylation of the corresponding acylphloroglucinols under alkaline conditions, whereby prenylation is performed in a mixture of water and an organic solvent immiscible with water, in the presence of a phase-transfer catalyst.

PROCESS FOR CREATING NON-CATALYSIS CARBON-CARBON BINDINGS FROM CARBONYL COMPOUNDS

Diffusion transfer photographic material containing a quinone-type compound with photographically useful group and ballast group

Abstract Photographic silver halide material for use in diffusion transfer photography and method using such material. Said material contains a quinone-type compound which corresponds to one of the formulae (A) or (B) and which is capable in reduced state and under alkaline conditions of releasing a photographically useful group e.g. a dye : (A) (B) wherein : each of (Nuox)1 and (Nuox)2 represents an oxidized nucleo-philic group, Z represents a bivalent atomic group which is electro-negative, Q together with the Z group represents a releasable photographically useful group, each of R1, R2 and R3 is hydrogen, halogen, alkyl, alkoxy, GV.1013 or an acylamino group or R1 and R2 in adjacent posi-tions on the ring form a ring fused with the remain-der of the molecule, or R2 and R3 together are fused with the remainder of the molecule, each of R4 and R5 represents hydrogen or a hydrocarbon group. At least one of the substituents R1, R2, R3, R4 or R5 is a ballasting group X. GV.1013